Q-omics provides the consensus-scored FBXO24 profile across patient tissues and cancer cell-line models. FBXO24 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBXO24 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, FBXO24 RNA expression shows 16,910 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where FBXO24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO24 survival associations across molecular data types. FBXO24 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO24 RNA expression–survival associations across cancer types. High FBXO24 expression shows unfavorable associations in KIRC, COAD, THCA, UVM and LGG, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBXO24 RNA expression.
This table summarizes FBXO24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FBXO24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO24 shows lower tumor expression in KIRC, THCA and UCEC and higher tumor expression in LIHC, LUAD and CHOL. The KIRC box plot shows higher FBXO24 RNA expression in normal versus tumor tissue (log2 FC = −0.210, t-test p < 0.001).
This table shows molecular features associated with FBXO24 in patient tissues and cancer cell lines. In patient samples, FBXO24 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
